| For immediate release |
|
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Results of General Meeting and Total Voting Rights
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine is pleased to announce that, at the General Meeting held earlier today, all the Resolutions were duly passed.
The full text of the Resolutions can be found in the Notice of General Meeting, which is contained in the Circular published and issued to shareholders on 23 October 2024 and is available on the Company's website at: www.oncimmune.com
The Company is pleased to confirm that as a result of obtaining shareholder approval for the resolutions required to implement the Fundraising, , the Company has raised total gross proceeds of approximately £2.3 million in aggregate from the Fundraising.
5,500,000 Firm Placing Shares and 500,000 Firm Subscription Shares were admitted to trading on AIM on 23 October 2024 on First Admission. Application has been made to the London Stock Exchange for the admission of a total of 31,631,072 new Ordinary Shares to trading on AIM pursuant to the Second Admission. Second Admission comprises (i) 6,500,000 Conditional Placing Shares; (ii) 1,833,333 Conditional Subscription Shares (iii) 22,351,003 Conversion Shares and (iv) 946,736 Retail Offer Shares. These new Ordinary Shares will rank pari passu with the Existing Ordinary Shares. Admission of the Conditional Placing Shares, Conditional Subscription Shares, Conversion Shares and Retail Offer Shares is expected to occur at 8:00 a.m. on 11 November 2024.
Total Voting Rights
Following Second Admission, the Company will have 111,773,219 Ordinary Shares in issue and there are no shares held in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
This announcement should be read in conjunction with the full text of the Circular posted to Shareholders on 23 October 2024. Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement of the Fundraising made by the Company on 18 October 2024.
For further information:
Oncimmune Holdings plc
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Ondraya Swanson (ECM)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King, Dan Bate
+44 (0)20 3829 5000
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.